Zejula (niraparib) - Update On The Maintenance Treatment In Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In The Second Or Later Line Setting
ZEJULA (niraparib), a medication used to treat recurrent ovarian, fallopian tube, or primary peritoneal cancer, is being recalled across Canada due to new safety information. The recall affects patients taking this drug for maintenance treatment in advanced disease settings. Health authorities have identified safety concerns that warrant this product recall.
- Product
- ZEJULA (niraparib)
- Reason
- New safety information
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2023-02-16
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/8cced300-e263-499d-bb84-7a57f8d82aef